Zydus Lifesciences has received final approval from the USFDA to market Colestipol Hydrochloride Tablets in the strength of 1mg US RLD Colestid Colestipol hydrochloride tablets are indicated as ...

Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C (low-density lipoprotein, known as bad cholesterol) in patients with ...

Do not crush, chew, or cut. Take with adequate fluids. Initially 2g once or twice daily, then increase by 2g once or twice daily at 1–2 month intervals. Usual maintenance: 2–16g/day in 1 or more ...

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated ...

Zydus Lifesciences has received final approval from the U. S. Food and Drug Administration (USFDA) to market its generic version of cholesterol lowering drug Colestipol Hydrochloride tablets, in the ...

There is an extensive literature now documenting the effects of lipid-lowering pharmacologic therapy in reducing atherosclerotic cardiovascular disease and events in adults. Children with familial ...

Zydus Lifesciences Ltd on Monday said it has received the final approval from the US health regulator to market its generic version of colestipol hydrochloride tablets, which is used to lower ...

Ahmedabad (Gujarat) [India], March 15 (ANI): Zydus Lifesciences Ltd. has received final approval from the United States Food and Drug Administration (USFDA) to market Colestipol Hydrochloride Tablets ...

The approval by the US Food and Drug Administration is for colestipol hydrochloride of 1 mg strength, the company said in a regulatory filing. Zydus Lifesciences Ltd on Monday said it has received the ...